The Expectations for UnitedHealth Following Earnings Report
UnitedHealth Group (UNH) is set to unveil its second-quarter results before the market opens on Tuesday. There’s a lot of anticipation about how the company’s shares will react throughout the week.
Recent options trading suggests that UnitedHealth’s stock could see a swing of more than 7% by the weekend. As of Monday afternoon, shares were holding steady around $281.
In April, when UnitedHealth last reported, the stock dropped over 22% after the company lowered its profit projections for the year. Historically, we’ve seen fluctuations with their shares — a dip of 6% and 8% on third and fourth-quarter report days, respectively, but a 6.5% increase following last year’s second-quarter results.
The stock has struggled considerably this year, losing about 45% of its value largely due to a disappointing first quarter and a sudden CEO departure, which is now under investigation by the Department of Justice regarding claims practices.
Yet, despite these setbacks, analysts remain optimistic. Out of 15 analysts tracked by Visible Alpha, 12 are suggesting a buy, with two holding steady and one recommending a sell. The average price target is set at $379.40.
For this quarter, revenue is projected to rise 13% to $111.88 billion, although earnings per share are expected to drop from $6.80 last year to $4.64.
Cheniere Energy Surges on US-EU Trade Deal
Cheniere Energy (LNG) saw its shares gain on Monday following a trade agreement between President Trump and European Commission President Ursula von der Leyen. The deal focuses on increasing LNG purchases from American suppliers.
The agreement states that 27 EU nations will collectively spend $750 billion on LNG and other energy sources from the U.S. over the next three years.
This energy deal is part of a broader trade arrangement, which includes a 15% tariff on EU exports to the U.S., thereby facilitating easier access for American exports. Additionally, the EU plans to invest $600 billion more in the U.S. market and significantly increase purchases of military equipment from American manufacturers.
Cheniere Energy’s stock rose 1.5% during Monday’s afternoon trading after an earlier increase of nearly 5% at the market open.
Positive Results in Breast Cancer Treatment Fuel Stock Rally
A biotech company reported promising late-stage results for its experimental breast cancer treatment, which led to a surge in some small-cap stocks on Monday.
The report highlighted that a Phase 3 trial for Gedatolisib achieved its primary endpoint. This drug, in combination with two others, parbociclib and fulvestrant, showed a 76% reduction in the risk of disease progression or death compared to using fulvestrant alone.
The trial involved patients with specific types of breast cancer, categorized as HR-positive and HER2-negative, providing potentially critical data for future treatments.
Dr. Igor Gorbatchevsky, who is the chief medical officer at Celcuity, expressed optimism that Gedatolisib could significantly change the treatment landscape for these patients.
Plans are in place for submitting a new drug application to the FDA for Gedatolisib in the fourth quarter.
With a year-to-date increase of 5%, Celcuity’s stock skyrocketed by 190% during recent trading, reaching around $40 after hitting over $46 earlier during Monday’s session.
JPMorgan Analyst Issues Strong Buy Recommendation for Nike
Nike (NKE) shares reached a five-month peak on Monday after JPMorgan reiterated its buy rating, citing the company’s effective turnaround strategy.
The analyst cleverly referenced Nike’s famous slogan, urging investors to consider the stock. They raised the price target from $64 to $93, indicating a strong outlook for Nike’s earnings over the next two years.
This positivity stemmed from a mix of recent evaluations, including market research and reviews of the company’s financial filings.
Analysts noted improvements in inventory management, expected sales growth, and an exciting pipeline of performance products, especially with the upcoming Football World Cup in the U.S. next year.
Despite a slight decrease of less than 1% on Monday, Nike’s stock opened at $79.99, boosting by 2.5% to around $78 during the latter part of trading.
Investors Eager for Insights from Major Tech Companies
This week, the top four companies—Microsoft (MSFT), Apple (AAPL), Amazon (AMZN), and Meta—are set to release their earnings results. AI investments are on many investors’ minds, driving interest in how these firms are adapting to the evolving tech landscape, although trade policies will likely come into play, particularly during the earnings calls for Apple and Amazon.
Microsoft and Meta will kick off the reporting period after market close on Wednesday, while Alphabet (GOOGL) and Tesla (TSLA) have already posted results. Nvidia (NVDA) will follow later in August.
Is AI investment still on the rise?
Just six months ago, there was some doubt on Wall Street about whether tech companies were overextending in AI. However, it appears the tide has turned, at least for now.
Last week, Alphabet raised its capital expenditure forecast to $85 billion, reflecting strong demand for cloud services. This news was generally well-received, with Google Cloud seeing a rise of over 30% year-on-year.
Microsoft and Amazon are likely observing Alphabet’s example, especially since they left their own forecasts unchanged three months ago amid prior trade uncertainties. With some of that uncertainty easing, they may now be more confident in ramping up AI investments.
Meta is also seen as a wildcard; although it recently increased its CAPEX outlook, such unpredictability isn’t new for them.
Will AI bring better monetization and efficiency?
There’s a demand for evidence that hefty investments in AI are yielding returns. Sundar Pichai, CEO of Alphabet, indicated that AI significantly benefits all business sectors while also driving growth.
During the last quarter, Meta expressed confidence that its AI investments are boosting ad effectiveness and user engagement. Investors will be keen to see if upcoming results confirm these expectations.
Similarly, Amazon may share updates about its AI shopping assistant, while Microsoft could provide details on its Copilot AI offerings.
Apple investors may have to wait a bit longer for detailed info. Analysts, especially from Morgan Stanley, don’t foresee major updates on Apple’s AI developments or changes in their capital expenditures for now.
How are tech giants managing tariffs?
In the near term, Apple investors may be particularly concerned about tariffs compared to their counterparts. Earlier this year, President Trump had exempted certain electronics from tariffs, but new security concerns have since raised the possibility of imposing Section 232 tariffs, which could complicate matters for Apple.
Even without tariffs, estimates suggested that costs could rise by about $900 million for Apple this quarter alone. Investors will be keeping a close eye on how Apple navigates these challenges.
Trade policies are also crucial for Amazon, which noted in Q1 that some customers were stockpiling to avoid potential tariffs. Though price increases weren’t significant early on, future tariff adjustments may depend on a variety of market factors.
Major Index Futures Indicate Positive Market Open
Futures tied to the Dow Jones Industrial Average saw a slight increase of 0.1%.
Meanwhile, S&P 500 futures also rose by 0.2%.
Nasdaq 100 futures gained 0.3% as well.
